Phosphorylation-Dependent 14-3-3 Binding to LRRK2 Is Impaired by Common Mutations of Familial Parkinson's Disease
暂无分享,去创建一个
Qing Jun Wang | B. Chait | Yingming Zhao | Sangkyu Lee | Z. Yue | Xianting Li | Nina Pan | Zhenyu Yue
[1] David I. Bass,et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice , 2010, Neurobiology of Disease.
[2] L. Petrucelli,et al. Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease , 2010, Nature Medicine.
[3] A. Reith,et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization , 2010, The Biochemical journal.
[4] A. Prescott,et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization , 2010, The Biochemical journal.
[5] J. Buxbaum,et al. Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019S , 2010, The Journal of Neuroscience.
[6] H. Cai,et al. Phosphorylation of Ezrin/Radixin/Moesin Proteins by LRRK2 Promotes the Rearrangement of Actin Cytoskeleton in Neuronal Morphogenesis , 2009, The Journal of Neuroscience.
[7] A. West,et al. Dependence of Leucine-rich Repeat Kinase 2 (LRRK2) Kinase Activity on Dimerization* , 2009, The Journal of Biological Chemistry.
[8] A. Pisani,et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice , 2009, Proceedings of the National Academy of Sciences.
[9] R. Burke,et al. Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease , 2009, Nature Neuroscience.
[10] Huadong Liu,et al. Molecular Characterization of Propionyllysines in Non-histone Proteins *S , 2009, Molecular & Cellular Proteomics.
[11] Wade Morishita,et al. RIM1α phosphorylation at serine-413 by protein kinase A is not required for presynaptic long-term plasticity or learning , 2008, Proceedings of the National Academy of Sciences.
[12] M. Cookson,et al. The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation* , 2008, Journal of Biological Chemistry.
[13] C. Chu,et al. Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cells , 2008, Journal of neurochemistry.
[14] M. Cookson,et al. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase , 2008, Proceedings of the National Academy of Sciences.
[15] C. Olanow,et al. Leucine‐rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson’s disease R1441C/G mutants , 2007, Journal of neurochemistry.
[16] Shu G. Chen,et al. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. , 2007, Experimental cell research.
[17] D. Maurice,et al. Protein Kinase A Phosphorylation of Human Phosphodiesterase 3B Promotes 14-3-3 Protein Binding and Inhibits Phosphatase-catalyzed Inactivation* , 2007, Journal of Biological Chemistry.
[18] T. Katada,et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. , 2007, Biochemistry.
[19] A. Abeliovich,et al. The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.
[20] C. Ross,et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.
[21] Ileana M. Cristea,et al. Induction of Autophagy in Axonal Dystrophy and Degeneration , 2006, The Journal of Neuroscience.
[22] David W. Miller,et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.
[23] M. Dai,et al. 14‐3‐3γ binds to MDMX that is phosphorylated by UV‐activated Chk1, resulting in p53 activation , 2006, The EMBO journal.
[24] M. Mann,et al. Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-trap*S , 2005, Molecular & Cellular Proteomics.
[25] C. Ross,et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[26] Yingming Zhao,et al. Integrated approach for manual evaluation of peptides identified by searching protein sequence databases with tandem mass spectra. , 2005, Journal of proteome research.
[27] Tohru Natsume,et al. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage , 2005, Nature Cell Biology.
[28] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[29] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[30] H. Saya,et al. PKA phosphorylation and 14‐3‐3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin , 2004, FEBS letters.
[31] Angus C Nairn,et al. DARPP-32: an integrator of neurotransmission. , 2004, Annual review of pharmacology and toxicology.
[32] S. Mangiavacchi,et al. Mechanisms by which Dopamine Receptors May Influence Synaptic Plasticity , 2003, Annals of the New York Academy of Sciences.
[33] Thomas C. Südhof,et al. Phosphorylation of RIM1α by PKA Triggers Presynaptic Long-Term Potentiation at Cerebellar Parallel Fiber Synapses , 2003, Cell.
[34] P. Cohen,et al. Regulation of BAD by cAMP-dependent protein kinase is mediated via phosphorylation of a novel site, Ser155. , 2000, The Biochemical journal.
[35] R. Liddington,et al. Mutations in the Hydrophobic Surface of an Amphipathic Groove of 14-3-3ζ Disrupt Its Interaction with Raf-1 Kinase* , 1998, The Journal of Biological Chemistry.
[36] M. Yaffe,et al. The Structural Basis for 14-3-3:Phosphopeptide Binding Specificity , 1997, Cell.
[37] Robert J. Lefkowitz,et al. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A , 1997, Nature.
[38] A. Craparo,et al. 14-3-3 (ε) Interacts with the Insulin-like Growth Factor I Receptor and Insulin Receptor Substrate I in a Phosphoserine-dependent Manner* , 1997, The Journal of Biological Chemistry.
[39] H. Wakui,et al. Interaction of the Ligand-activated Glucocorticoid Receptor with the 14-3-3η Protein* , 1997, The Journal of Biological Chemistry.
[40] T. L. Collins,et al. Direct interaction between protein kinase C theta (PKC theta) and 14-3-3 tau in T cells: 14-3-3 overexpression results in inhibition of PKC theta translocation and function , 1996, Molecular and cellular biology.
[41] F. McCormick,et al. Bcr and Raf form a complex in vivo via 14‐3‐3 proteins. , 1995, The EMBO journal.
[42] A. Wynshaw-Boris,et al. Role of 14-3-3 proteins in eukaryotic signaling and development. , 2005, Current topics in developmental biology.
[43] Daniel Thomas,et al. 14-3-3 protein signaling in development and growth factor responses. , 2005, Current topics in developmental biology.
[44] S. Masters,et al. 14-3-3 proteins: structure, function, and regulation. , 2000, Annual review of pharmacology and toxicology.